LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aktien・Gossamer Bio Inc

Gossamer Bio Inc

Geschlossen

BrancheGesundheitswesen

0.21

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.19

Max

0.22

Schlüsselkennzahlen
By Trading Economics
Einkommen	574K -47M
Verkäufe	3.2M 17M
EPS	-0.2
Gewinnspanne	-275.223
Angestellte	161
EBITDA	1.2M -45M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+2318.18% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-30M 49M
Vorheriger Eröffnungskurs	0.21
Vorheriger Schlusskurs	0.21

Nachrichtenstimmung

By Acuity

90%

10%

326 / 344 Ranking in Healthcare

Gossamer Bio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

27. Mai 2026, 21:33 UTC

Ergebnisse

Correction to Salesforce 1Q Sales, Profit Rise Article

27. Mai 2026, 21:00 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare Agrees to Buy The College of Health Care Professions

27. Mai 2026, 20:18 UTC

Ergebnisse

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27. Mai 2026, 23:49 UTC

Market Talk

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27. Mai 2026, 23:39 UTC

Market Talk

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27. Mai 2026, 23:34 UTC

Market Talk

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27. Mai 2026, 23:34 UTC

Market Talk

Global Equities Roundup: Market Talk

27. Mai 2026, 23:08 UTC

Market Talk

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27. Mai 2026, 22:21 UTC

Market Talk

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27. Mai 2026, 21:29 UTC

Heiße Aktien

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27. Mai 2026, 21:08 UTC

Ergebnisse

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27. Mai 2026, 21:02 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27. Mai 2026, 20:59 UTC

Akquisitionen, Fusionen, Übernahmen

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27. Mai 2026, 20:55 UTC

Ergebnisse

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27. Mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. Mai 2026, 20:48 UTC

Ergebnisse

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27. Mai 2026, 20:45 UTC

Ergebnisse

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27. Mai 2026, 20:34 UTC

Akquisitionen, Fusionen, Übernahmen

Webster Financial Stockholders Approve Sale to Banco Santander

27. Mai 2026, 20:32 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27. Mai 2026, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27. Mai 2026, 20:32 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27. Mai 2026, 20:30 UTC

Ergebnisse

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27. Mai 2026, 20:30 UTC

Akquisitionen, Fusionen, Übernahmen

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27. Mai 2026, 20:22 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. Mai 2026, 20:16 UTC

Ergebnisse

Salesforce Stock Slides on Mixed Results -- Barrons.com

27. Mai 2026, 20:13 UTC

Ergebnisse

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27. Mai 2026, 20:13 UTC

Ergebnisse

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27. Mai 2026, 20:13 UTC

Ergebnisse

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27. Mai 2026, 20:12 UTC

Ergebnisse

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27. Mai 2026, 20:12 UTC

Ergebnisse

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Peer-Vergleich

Kursveränderung

Gossamer Bio Inc Prognose

Kursziel

By TipRanks

2318.18% Vorteil

12-Monats-Prognose

Durchschnitt 5.32 USD 2318.18%

Hoch 15 USD

Tief 0.28 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gossamer Bio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

6 ratings

Buy

Halten

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gossamer Bio Inc – Dist abgegeben haben.

Stimmung

By Acuity

326 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.